Pharsight

Rebetol patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6790837 SCHERING Ribavirin syrup formulations
Apr, 2023

(5 months ago)

US6790837

(Pediatric)

SCHERING Ribavirin syrup formulations
Oct, 2023

(6 days from now)

Rebetol is owned by Schering.

Rebetol contains Ribavirin.

Rebetol has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Rebetol are:

  • US6790837

Rebetol was authorised for market use on 29 July, 2003.

Rebetol is available in solution;oral dosage forms.

The generics of Rebetol are possible to be released after 05 October, 2023.

Drugs and Companies using RIBAVIRIN ingredient

Market Authorisation Date: 29 July, 2003

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage

REBETOL family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic